Voya Financial, Inc. (VOYA) Reaches $49.98 After 3.00% Down Move; Last Week Novavax, Inc. (NVAX) Analysts

February 15, 2018 - By Dolores Ford

Among 12 analysts covering Novavax (NASDAQ:NVAX), 4 have Buy rating, 0 Sell and 8 Hold. Therefore 33% are positive. Novavax had 26 analyst reports since August 11, 2015 according to SRatingsIntel. On Wednesday, November 8 the stock rating was maintained by Cantor Fitzgerald with “Hold”. The firm has “Hold” rating by Piper Jaffray given on Tuesday, September 19. The rating was initiated by Chardan Capital Markets on Monday, April 4 with “Neutral”. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Buy” rating by Ladenburg on Thursday, January 11. Citigroup downgraded the stock to “Neutral” rating in Tuesday, December 19 report. The stock of Novavax, Inc. (NASDAQ:NVAX) has “Neutral” rating given on Friday, September 16 by Wedbush. Cantor Fitzgerald maintained it with “Hold” rating and $2.0 target in Tuesday, November 14 report. The stock has “Hold” rating by Piper Jaffray on Monday, July 24. The firm earned “Neutral” rating on Friday, September 16 by Ladenburg Thalmann. The firm earned “Neutral” rating on Tuesday, September 20 by Chardan Capital Markets. See Novavax, Inc. (NASDAQ:NVAX) latest ratings:

11/01/2018 Broker: FBR Capital Rating: Buy New Target: $10.0 Maintain
11/01/2018 Broker: Ladenburg Rating: Buy New Target: $2.5 Maintain
05/01/2018 Broker: B. Riley & Co Rating: Buy New Target: $2.25 Initiates Coverage On
05/01/2018 Broker: FBR Capital Rating: Buy New Target: $2.25
19/12/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade
14/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
08/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
31/10/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade
06/10/2017 Broker: Seaport Global Rating: Neutral Initiates Coverage On
19/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $1.5 Maintain




The stock of Voya Financial, Inc. (NYSE:VOYA) is a huge mover today! The stock decreased 2.36% or $1.21 during the last trading session, reaching $49.98. About 1.23M shares traded. Voya Financial, Inc. (NYSE:VOYA) has risen 11.06% since February 15, 2017 and is uptrending. It has underperformed by 5.64% the S&P500.The move comes after 5 months negative chart setup for the $8.98B company. It was reported on Feb, 15 by Barchart.com. We have $48.48 PT which if reached, will make NYSE:VOYA worth $269.52M less.

Investors sentiment increased to 0.74 in 2017 Q3. Its up 0.02, from 0.72 in 2017Q2. It is positive, as 27 investors sold Voya Financial, Inc. shares while 131 reduced holdings. 34 funds opened positions while 83 raised stakes. 168.54 million shares or 1.33% less from 170.81 million shares in 2017Q2 were reported. Chase Invest Counsel invested 0.19% of its portfolio in Voya Financial, Inc. (NYSE:VOYA). Natixis accumulated 81,062 shares. Sumitomo Mitsui Trust accumulated 660,728 shares or 0.04% of the stock. Highbridge Ltd Liability Co invested in 0.25% or 410,500 shares. First Commonwealth Financial Corporation Pa stated it has 13,145 shares. Scout Inc reported 775,140 shares. Invesco Limited accumulated 7.68 million shares. The Maryland-based Clearbridge Limited Company has invested 0.88% in Voya Financial, Inc. (NYSE:VOYA). Virginia Retirement Et Al owns 171,400 shares for 0.08% of their portfolio. Advisory holds 314,667 shares or 0.2% of its portfolio. Lord Abbett Limited Liability reported 97,900 shares. Voya Mngmt Ltd holds 51,391 shares. First Quadrant Ltd Partnership Ca invested in 65,580 shares. Oregon Employees Retirement Fund holds 0.02% or 34,867 shares. Dekabank Deutsche Girozentrale reported 21,992 shares stake.

Voya Financial, Inc. operates as a retirement, investment, and insurance firm in the United States. The company has market cap of $8.98 billion. It operates through five divisions: Retirement, Investment Management, Annuities, Individual Life, and Employee Benefits. It currently has negative earnings. The Retirement segment offers tax-deferred employer-sponsored retirement savings plans and administrative services in corporate, education, healthcare, and other non-profit and government entities; and rollover individual retirement accounts and other retail financial products, as well as financial planning and advisory services.

Among 17 analysts covering Voya Financial (NYSE:VOYA), 13 have Buy rating, 1 Sell and 3 Hold. Therefore 76% are positive. Voya Financial had 41 analyst reports since August 26, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Evercore given on Thursday, December 21. JP Morgan upgraded the stock to “Neutral” rating in Thursday, February 11 report. The company was upgraded on Tuesday, September 8 by Zacks. As per Wednesday, November 9, the company rating was downgraded by RBC Capital Markets. Keefe Bruyette & Woods maintained Voya Financial, Inc. (NYSE:VOYA) rating on Thursday, August 31. Keefe Bruyette & Woods has “Buy” rating and $50.0 target. RBC Capital Markets maintained it with “Buy” rating and $50.0 target in Wednesday, November 1 report. Keefe Bruyette & Woods maintained the stock with “Buy” rating in Friday, June 23 report. The stock of Voya Financial, Inc. (NYSE:VOYA) earned “Buy” rating by Sandler O’Neill on Monday, November 13. As per Tuesday, August 1, the company rating was maintained by Wells Fargo. As per Friday, November 10, the company rating was maintained by Keefe Bruyette & Woods.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $662.62 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

The stock increased 0.99% or $0.02 during the last trading session, reaching $2.05. About 2.26 million shares traded. Novavax, Inc. (NASDAQ:NVAX) has declined 79.61% since February 15, 2017 and is downtrending. It has underperformed by 96.31% the S&P500.

Investors sentiment increased to 1.26 in 2017 Q3. Its up 0.24, from 1.02 in 2017Q2. It improved, as 10 investors sold Novavax, Inc. shares while 29 reduced holdings. 14 funds opened positions while 35 raised stakes. 113.94 million shares or 6.86% less from 122.33 million shares in 2017Q2 were reported. D E Shaw & holds 446,101 shares or 0% of its portfolio. Alliancebernstein Lp accumulated 310,601 shares. Blackrock accumulated 24.19 million shares or 0% of the stock. Moreover, Edgemoor Advisors has 0.01% invested in Novavax, Inc. (NASDAQ:NVAX). Bank Of New York Mellon accumulated 0% or 1.36M shares. Vanguard holds 12.83M shares or 0% of its portfolio. California Pub Employees Retirement Systems reported 0% in Novavax, Inc. (NASDAQ:NVAX). Fifth Third Bancorp stated it has 100 shares. New York State Common Retirement Fund stated it has 297,240 shares. Legal And General Group Public Ltd Company has invested 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). Da Davidson And holds 0% or 77,150 shares in its portfolio. Teacher Retirement Systems Of Texas reported 22,219 shares stake. Artal Group Sa stated it has 0.01% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). Raymond James & Assoc has 70,381 shares for 0% of their portfolio. Bb Biotech Ag has 0.26% invested in Novavax, Inc. (NASDAQ:NVAX).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.